Drugs / Gelaspan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT02808325 | Jun 2016 → Jun 2017 | dehydration polycythemia | B. Braun Medical SA | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02715466 | Apr 2016 → Dec 2021 | — | B. Braun Melsungen AG | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03246659 Background | Aug 2016 → Nov 2018 | medullary thyroid gland carcinoma | Paola Anna Erba | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gelaspan | “Gelaspan combined with Sterofundin ISO” NCT02715466 ↗ |
| Modality | Other / unclassified | “gelatine solution” NCT02715466 ↗ |